Hudson Robotics Introduces Faster, More Efficient ADME-Tox Screening System

Hudson Robotics, Inc. today introduced the new VaryScreen™ ADME-Tox integrated workstation for faster, accurate and more efficient profiling of the absorption, distribution, metabolism and excretion (ADME) properties of drug molecules. VaryScreen ADME-Tox enables researchers to perform screens starting with just a single plate, yielding a complete profile more quickly and at a lower cost.

"Automating ADME profiling on the VaryScreen ADME-Tox single workcell provides the speed, accuracy and efficiency that investigators need at this critical point in drug development," said Alan Katz, chief scientific officer of Hudson Robotics. "The VaryScreen ADME-Tox system will perform ADME profiling up to three times faster than current processes. It performs the variety of assays required, yet demands less intervention by the user and less compound while delivering quality results."

The basic VaryScreen ADME system contains everything needed to support biochemical assays that measure the physicochemical properties of a drug molecule (ie. solubility, lipophilicity, pKa, protein binding). It supports PAMPA and CACO 2 permeability assays and can measure a drug's affinity toward such key toxilogical targets as hERG and various CYP metabolic enzymes.

Controlled by Hudson Robotics's SoftLinx scheduling software, VaryScreen ADME-Tox comes with sample protocols for each of the included ADME/Toxicity methods. The protocols are easily modified to meet user requirements, and more assays can be added to further customize follow-up screening efforts. VaryScreen ADME-Tox includes a multi-mode reader that not only supports the wide range of protocols, but also runs primary and secondary screens. This enables ADME/Tox profiling to be carried out automatically on hits found in the assays.